Provincial Health Services Authority (PHSA) improves the health of British Columbians by seeking province-wide solutions to specialized health care needs in collaboration with BC health authorities and other partners.
(corrected to exclude death from intercurrent disease)
It should be noted that these figures are approximations of five-year survival data collected from large numbers of patients within a given stage. Extreme caution should be used in attempting to use these data to assign prognosis in an individual case.
Revised: March 2000
Adenocarcinoma of the fallopian tube is a rare entity. Its management is the same as for
adenocarcinoma of the ovary.
Some gynecologic tumours are considered to be hormone responsive (i.e., some low grade uterine sarcomas). Estrogen replacement in this group of patients should be for symptomatic control. A thorough discussion with the patient of the potential risks and anticipated benefits of such treatment should take place.
Recommendation: continuous estrogen plus progestogen.
Patients should be reminded that it is their responsibility to keep their recommended follow-up appointments. The objectives of the follow-up visits are as follows:
These objectives are best met by having the initial follow-up examination performed by the Agency medical staff. When appropriate, arrangements will be made for follow-up by the referring physician.
BC Cancer Agency. All Rights Reserved.